325 related articles for article (PubMed ID: 25431954)
1. Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma.
Giovannini C; Minguzzi M; Baglioni M; Fornari F; Giannone F; Ravaioli M; Cescon M; Chieco P; Bolondi L; Gramantieri L
Oncotarget; 2014 Nov; 5(21):10607-20. PubMed ID: 25431954
[TBL] [Abstract][Full Text] [Related]
2. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.
Fornari F; Gramantieri L; Giovannini C; Veronese A; Ferracin M; Sabbioni S; Calin GA; Grazi GL; Croce CM; Tavolari S; Chieco P; Negrini M; Bolondi L
Cancer Res; 2009 Jul; 69(14):5761-7. PubMed ID: 19584283
[TBL] [Abstract][Full Text] [Related]
3. miR-451 inhibits cell proliferation in human hepatocellular carcinoma through direct suppression of IKK-β.
Li HP; Zeng XC; Zhang B; Long JT; Zhou B; Tan GS; Zeng WX; Chen W; Yang JY
Carcinogenesis; 2013 Nov; 34(11):2443-51. PubMed ID: 23740840
[TBL] [Abstract][Full Text] [Related]
4. Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 protein.
Dong C; Zhao B; Long F; Liu Y; Liu Z; Li S; Yang X; Sun D; Wang H; Liu Q; Liang R; Li Y; Gao Z; Shao S; Miao QR; Wang L
Oncotarget; 2016 Feb; 7(8):8850-65. PubMed ID: 26840457
[TBL] [Abstract][Full Text] [Related]
5. p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma.
Fornari F; Milazzo M; Galassi M; Callegari E; Veronese A; Miyaaki H; Sabbioni S; Mantovani V; Marasco E; Chieco P; Negrini M; Bolondi L; Gramantieri L
Mol Cancer Res; 2014 Feb; 12(2):203-16. PubMed ID: 24324033
[TBL] [Abstract][Full Text] [Related]
6. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-362-5p promotes tumor growth and metastasis by targeting CYLD in hepatocellular carcinoma.
Ni F; Zhao H; Cui H; Wu Z; Chen L; Hu Z; Guo C; Liu Y; Chen Z; Wang X; Chen D; Wei H; Wang S
Cancer Lett; 2015 Jan; 356(2 Pt B):809-18. PubMed ID: 25449782
[TBL] [Abstract][Full Text] [Related]
8. Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism.
Giovannini C; Gramantieri L; Chieco P; Minguzzi M; Lago F; Pianetti S; Ramazzotti E; Marcu KB; Bolondi L
J Hepatol; 2009 May; 50(5):969-79. PubMed ID: 19304334
[TBL] [Abstract][Full Text] [Related]
9. miR-15b-5p induces endoplasmic reticulum stress and apoptosis in human hepatocellular carcinoma, both in vitro and in vivo, by suppressing Rab1A.
Yang Y; Hou N; Wang X; Wang L; Chang S; He K; Zhao Z; Zhao X; Song T; Huang C
Oncotarget; 2015 Jun; 6(18):16227-38. PubMed ID: 26023735
[TBL] [Abstract][Full Text] [Related]
10. A novel all-trans retinoic acid derivative 4-amino‑2‑trifluoromethyl-phenyl retinate inhibits the proliferation of human hepatocellular carcinoma HepG2 cells by inducing G0/G1 cell cycle arrest and apoptosis via upregulation of p53 and ASPP1 and downregulation of iASPP.
Liu H; Chen F; Zhang L; Zhou Q; Gui S; Wang Y
Oncol Rep; 2016 Jul; 36(1):333-41. PubMed ID: 27177208
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of role of Notch3 signaling pathway in human lung cancer cells.
Hassan WA; Yoshida R; Kudoh S; Motooka Y; Ito T
J Cancer Res Clin Oncol; 2016 May; 142(5):981-93. PubMed ID: 26838758
[TBL] [Abstract][Full Text] [Related]
12. Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma.
Gramantieri L; Giovannini C; Lanzi A; Chieco P; Ravaioli M; Venturi A; Grazi GL; Bolondi L
Liver Int; 2007 Sep; 27(7):997-1007. PubMed ID: 17696940
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-105 suppresses cell proliferation and inhibits PI3K/AKT signaling in human hepatocellular carcinoma.
Shen G; Rong X; Zhao J; Yang X; Li H; Jiang H; Zhou Q; Ji T; Huang S; Zhang J; Jia H
Carcinogenesis; 2014 Dec; 35(12):2748-55. PubMed ID: 25280563
[TBL] [Abstract][Full Text] [Related]
14. IGF-I receptor as an emerging potential molecular-targeted for hepatocellular carcinoma in vitro and in vivo.
Yao M; Wang L; Yang J; Yan X; Cai Y; Yao D
Tumour Biol; 2016 Nov; 37(11):14677-14686. PubMed ID: 27623941
[TBL] [Abstract][Full Text] [Related]
15. RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma.
Ye J; Liang R; Bai T; Lin Y; Mai R; Wei M; Ye X; Li L; Wu F
J Exp Clin Cancer Res; 2018 Sep; 37(1):212. PubMed ID: 30176896
[TBL] [Abstract][Full Text] [Related]
16. [ShRNA-mediated silencing of MDM2 inhibits growth of HepG2 hepatocellular carcinoma cells xenografted in nude mice].
Zhao YY; Li YG; Sun YJ; Liu HP; Yang ZC; Zhang DD; Zhao CY
Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):213-7. PubMed ID: 23967744
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of PICT1 in patients of hepatocellular carcinoma with wild-type TP53.
Ishibashi M; Kogo R; Shibata K; Ueo H; Uchi R; Matsumura T; Takano Y; Sawada G; Takahashi Y; Mima K; Kurashige J; Akiyoshi S; Iwaya T; Eguchi H; Sudo T; Sugimachi K; Suzuki A; Wakabayashi G; Mori M; Mimori K
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S537-44. PubMed ID: 23532381
[TBL] [Abstract][Full Text] [Related]
18. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
[TBL] [Abstract][Full Text] [Related]
19. Deregulated expression of Notch receptors in human hepatocellular carcinoma.
Gao J; Song Z; Chen Y; Xia L; Wang J; Fan R; Du R; Zhang F; Hong L; Song J; Zou X; Xu H; Zheng G; Liu J; Fan D
Dig Liver Dis; 2008 Feb; 40(2):114-21. PubMed ID: 17920003
[TBL] [Abstract][Full Text] [Related]
20. Notch and Wnt/β-catenin signaling pathway play important roles in activating liver cancer stem cells.
Wang R; Sun Q; Wang P; Liu M; Xiong S; Luo J; Huang H; Du Q; Geller DA; Cheng B
Oncotarget; 2016 Feb; 7(5):5754-68. PubMed ID: 26735577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
